Search
Iproniazid
go.drugbank.com/drugs/DB04818ApprovedWithdrawnWithdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesGivinostat
go.drugbank.com/drugs/DB12645ApprovedInvestigationalIn the context of muscular dystrophy, inhibitors of HDAC appear to exert their therapeutic effects by targeting pathogenic processes that cause inflammation and muscle loss. … [L50311,L50316] It is the first non-steroidal drug approved to treat patients with all genetic variants of DMD.[L50316]
Bucetin
go.drugbank.com/drugs/DB13278ApprovedWithdrawnBucetin is an analgesic and antipyretic medication which was approved for use in Germany but was withdrawn from the market in 1986 due to renal toxicity caused by the medication.[A175636]
Zimelidine
go.drugbank.com/drugs/DB04832ApprovedWithdrawnZimelidine has been banned worldwide due to serious, sometimes fatal, cases of central and/or peripheral neuropathy known as Guillain-Barré syndrome and due to a peculiar hypersensitivity reaction involving … Additionally, zimelidine was charged to cause an increase in suicidal ideation and/or attempts among depressive patients.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesThioproperazine
go.drugbank.com/drugs/DB01622ApprovedIt is used for the treatment of all types of acute and chronic schizophrenia, including those which did not respond to the usual neuroleptics; manic syndromes. … It is virtually without antiserotonin and hypotensive action and has no antihistaminic property.
Phenyl salicylate
go.drugbank.com/drugs/DB11071ApprovedIt is an active ingredient in some pharmaceutical products as a mild analgesic for pain relief by releasing salicylate (found in [DB00945] ). … These are polycyclic compounds that is either a polyphenolic compound composed of two or more monocyclic aromatic units linked by an ester bond (depside), or a compound containing the depsidone structure
Mixtures: Urimar-T, Urimar-TLeptin
go.drugbank.com/drugs/DB05098InvestigationalThese people are said to be resistant to the effects of leptin, in much the same way that people with type 2 diabetes are resistant to the effects of insulin. … The high sustained concentrations of leptin from the enlarged fat stores result in the cells that respond to leptin becoming desensitized.
Treprostinil
go.drugbank.com/drugs/DB00374ApprovedInvestigationalTreprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension. … However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature.
Chenodeoxycholic acid
go.drugbank.com/drugs/DB06777ApprovedInvestigationalIt works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decrease the formation of gallstones. … It can also reduce the amount of other bile acids that can be harmful to liver cells when levels are elevated.
Dydrogesterone
go.drugbank.com/drugs/DB00378ApprovedInvestigationalWithdrawnA synthetic progestational hormone with no androgenic or estrogenic properties. … Unlike many other progestational compounds, dydrogesterone produces no increase in temperature and does not inhibit ovulation.